Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Mallinckrodt
Boehringer Ingelheim
Colorcon
Medtronic

Last Updated: February 4, 2023

Details for Patent: 8,062,652


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,062,652 protect, and when does it expire?

Patent 8,062,652 protects SUPPRELIN LA and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 8,062,652
Title:Compositions and methods for treating precocious puberty
Abstract: The present invention is directed to the controlled delivery of gonadotropin-releasing hormone (GnRH) agonists, preferably from a polymeric material that is implanted in the body. More specifically, the present invention relates to compositions comprised of a GnRH agonist, preferably histrelin, in a polymeric material that results in a desired and controlled delivery of a therapeutically effective amount of GnRH agonist over an extended period of time in order to treat central precocious puberty (CPP).
Inventor(s): Kuzma; Petr (Princeton, NJ)
Assignee: Endo Pharmaceuticals Solutions Inc. (Chadds Ford, PA)
Application Number:11/155,822
Patent Claim Types:
see list of patent claims
Use; Formulation; Device;

Drugs Protected by US Patent 8,062,652

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Endo Pharm SUPPRELIN LA histrelin acetate IMPLANT;SUBCUTANEOUS 022058-001 May 3, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,062,652

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2570960 See Plans and Pricing
European Patent Office 1773293 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006009801 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Merck
Colorcon
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.